Searchable abstracts of presentations at key conferences in endocrinology

ea0070ep107 | Bone and Calcium | ECE2020

Ectopic parathyroid hormone secretion by a squamous cell carcinoma of the floor of the mouth with poor response to cinacalcet

Bilbao Ismene , Egaña Nerea , Rojo Jorge , Garcia Cristina , Olaizola Izaskun , Agea Leire , Aranburu Maite , Yoldi Alfredo , Goena Miguel

Introduction: Ectopic PTH secretion is rare, to our knowledge, with only 27 cases reported in the literature and 3, ( a tonsil, a lung and a penile) due to squamous cell carcinoma .In the few cases reported to date it appears to be more common in males and in those over the age of 60. The management of the hypercalcemia in this setting is complicated. We are aware of 2 other case reports in which cinacalcet was used in this context, but as in our case, unsuccessfully.<p cl...

ea0056p1178 | Thyroid cancer | ECE2018

Malignancy risk stratification of thyroid nodules with cytological diagnosis of folicular neoplasm (Bethesda IV), according to the ultrasound sonographic patterns proposed by the American Thyroid Association (ATA)

Pineda Jose Javier , Ernaga Ander , Anda Emma , Toni Marta , Martinez Juan Pablo , Munarriz Patricia , Rojo Jorge , Ollero Dolores , Diaz Maria

Background: The main limitation of fine-needle aspiration (FNA) is represented by indeterminate category (Bethesda III and IV) in which the risk of malignancy is between 5-30%. Given this result, surgical treatment is necessary in many cases. The aim of our study is to assess whether the ultrasound patterns proposed by the ATA, help us to stratify the risk of malignancy in nodules with Bethesda IV cytology result.Methods: From January 2011 to June 2017 w...

ea0081p687 | Pituitary and Neuroendocrinology | ECE2022

Plurihormonal pituitary macroadenoma, co −secreting TSH/GH/and prolactin: a clinical challenge

Bilbao Garay Ismene , Egana Nerea , Perez De Ciriza Maite , Chinchurreta Laura , Elias Cristina , Venegas Inmaculada , Amilibia Ane , Garcia Cristina , Rojo Jorge , Yoldi Alfredo

Background: Co secreting Thyrotropin/growth hormone pituitary adenomas are rare, and their clinical presentation and long term management may be challenging. Clinically, the majority of plurihormonal pituitary adenomas are silent and diagnosis almost always relies on immunohistochemical analysis of the tumor tissue. Early detection is key to optimize patient mamagement. We report a case of pituitary plurihormonal macroadenoma with overt clinical hyperthyroidism and minimal GH ...

ea0081ep1080 | Thyroid | ECE2022

Neutropenia in hyperthyroidism

Elias Ortega Cristina , Zunzunegui Nerea Egan a , Delgado Cristina Garcia , Calafell Maria Teresa Aramburu , Alvaro Jorge Rojo , Nebreda Inmaculada Venegas , Achucarro Ane Amilibia , Garay Ismene Bilbao , Arrieta Alfredo Yoldi

Introduction: Neutropenia can indicate infectious and hematological pathology but it can also be a sign of hyperthyroidism. For this reason, it has been suggested to perform a complete blood count before starting treatment with antithyroid drugs in case of new-onset hyperthyroidism. Antithyroid drugs can cause severe neutropenia, also called agranulocytosis, when the neutrophil count is less than 500/µl. Therefore, the use of these drugs should be reconsidered if it is le...

ea0070ep351 | Pituitary and Neuroendocrinology | ECE2020

Cardiovascular risk factors in acromegaly: comparison between successful surgery with medical treatment

Egaña Zunzunegui Nerea , Bilbao Ismene , García Cristina , Aramburu Maite , Agea Leire , Olaizola Izaskun , Rojo Jorge , Yoldi Alfredo , Goena Miguel

Introduction: Acromegaly is an insidious disease caused by chronic GH and IGF-I hypersecretion associated with increased morbidity and mortality, mostly from cardiovascular complications. The aim of this study is to compare cardiovascular risk factors, between patients with medical treatment vs cured.Materials and methods: This is a retrospective study of 37 acromegalic patients, 21 well controlled with medical treatment (IGF-I within the normal range fo...

ea0073aep160 | Diabetes, Obesity, Metabolism and Nutrition | ECE2021

Could we use SGLT2 inhibitors without serious concern in the elderly?

Ihintza Larrañaga , Vives Cristina Goena , Maria Magdalena Arteaga Ossa , Alvaro Jorge Rojo , Laura Mañas Alonso , Ovejero Laura Quintas , Begoña Maíz Alcorta , Rodrigo Ana Moreno , Nerea Andrés Imaz , Irene Larrañaga Gomez , Villar Ruth Agirrezabalaga , Abasolo Amaia Aspiazu , Suarez Teresa Arana , Dadebat Naroa Rico , Amaia Cristina Armentia Del Pozo , Irizar Sara Diez , Tijero Naroa Gomez , Jose Francisco Egido Arroyo

BackgroundTherapeutic experience with SGLT2i is limited in the elderly. Its initiation is not recommended in patients over 85 years based on volume depletion risk. The aim of this study is to analyze clinical efficacy and safety of SGLT2i in elder T2DM patients.MethodsThis observational retrospective study included 544 T2DM subjects who initiated SGLT2i as add-on treatment between February 2018–2019 and ...